Pfizer names Cecile Guegan CFO; files show Q3 revenue and guidance raise
Pfizer elected Cecile Guegan as chief financial officer and EVP, effective Nov. 1, 2026, while its SEC filings show $16.6B Q3 revenue and a raised full-year outlook.
Published by Vero, the Intelligence Operating System for investors: news scored for importance, thesis tracking and an AI investing copilot, for long-term investors and active traders.
Pfizer has made Cecile Guegan its chief financial officer and executive vice president, according to the company’s recent SEC filings. The filings also include the company’s third-quarter results and a routine quarterly report.
Appointment details from the 8-K
In an 8-K filed with the SEC (Item 5.02) on Nov. 3, 2026, Pfizer disclosed that Cecile Guegan was elected Chief Financial Officer and Executive Vice President, effective Nov. 1, 2026. The filing says she had served as interim CFO beginning Aug. 16, 2026.
Compensation disclosed
The same 8-K lists Ms. Guegan’s compensation terms: a $1.3 million base salary and a $1.3 million target cash incentive, per the disclosure in the filing (Item 5.02).
Quarterly results and guidance
Separately, Pfizer filed an 8-K (Item 2.02) reporting third-quarter 2026 results. The filing shows third-quarter revenues of $16.6 billion and says the company raised its full-year guidance for revenue and adjusted earnings per share. The 8-K also reports that non-COVID products grew during the quarter and that launched and acquired products rose 32% on an operating basis.
The Item 2.02 filing also states that a one-time Acquired In-Process Research & Development (IPR&D) charge of $650 million reduced the quarter’s reported earnings per share by about $0.10.
Regulatory filing note
Pfizer filed its quarterly Form 10-Q for the period ended Sept. 27, 2026, the company noted in a separate SEC filing. The 10-Q is described as a routine regulatory update that summarizes Pfizer’s results and financial condition; the text provided to Vero did not include additional figures or explanations from that filing.
All items in this report are drawn from Pfizer’s SEC filings dated Nov. 3, 2026 (8-K and 10-Q), as summarized above.
Sources
This article was written from the reporting below. Every claim should be checkable against one of these. Entries without a link are cited by outlet and date so you can look them up.